TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31779926

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Other medications
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis (n=1,439)
Number of subjects: 1846
Study: 31779928

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Cumulative comorbidity score
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Primary composite endpoint (all-cause mortality or hospitalization)
Number of subjects: 2331
Study: 31780140

Group type: EXPERIMENTAL
Intervention: Medication-related adverse events (MRE) in anaesthesia care
Number of subjects: 7072

Group type: EXPERIMENTAL
Intervention: Vasoconstrictor agents, benzodiazepines, and neuromuscular blocking agents
Number of subjects: 7072

Group type: EXPERIMENTAL
Intervention: Local corrective patient safety and quality improvement measures
Number of subjects: 7072
Study: 31780237

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Tc
Number of subjects: 65
Study: 31780255

Group type: EXPERIMENTAL
Intervention: Atezolizumab (15 mg/kg for patients <18 years, 1200 mg for patients 18-29 years)
Number of subjects: 90
Study: 31780963

Group type: EXPERIMENTAL
Intervention: Kundalini Yoga Meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation Response Meditation
Number of subjects: 0
Study: 31780970

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 31781021

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31781386

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (exercise and/or nutrition)
Number of subjects: 61
Study: 31781889

Group type: EXPERIMENTAL
Intervention: Stress group (SG) with PSS-10 ≥ 19
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (CG) with PSS-10 < 19
Number of subjects: 110
Study: 31781957

Group type: EXPERIMENTAL
Intervention: Sedentary behavior (15 MET-h/week)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Total physical activity (148 MET-h/week)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Sedentary behavior as a predictor of preeclampsia
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Total physical activity and sedentary behavior
Number of subjects: 189
Study: 31782492

Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Urinary TMAO
Number of subjects: 4680
Study: 31783178

Group type: EXPERIMENTAL
Intervention: Assessment of ALK translocation by FISH
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: RNA sequencing
Number of subjects: 32
Study: 31783773

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol serum levels ≥ 20 mg/L
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol serum levels > 40 mg/L
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Anti-drug antibodies detected in serum samples
Number of subjects: 268
Study: 31783791

Group type: EXPERIMENTAL
Intervention: ST elevation myocardial infarction (STEMI) management and outcomes
Number of subjects: 5479
Study: 31783816

Group type: EXPERIMENTAL
Intervention: Precision radiotherapy (volumetric modulated arc therapy or stereotactic body radiotherapy) with 18 × 2.33Gy in 3.5 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional radiotherapy with 10x3Gy in 2 weeks
Number of subjects: 65
Study: 31783832

Group type: EXPERIMENTAL
Intervention: Behavioral health risk factor screening and brief intervention targeting two or more HRFs
Number of subjects: 6251

Group type: EXPERIMENTAL
Intervention: Behavioral health risk factor profiles including overweight, alcohol, and/or smoking
Number of subjects: 6251

Group type: EXPERIMENTAL
Intervention: Interventions targeting two or more HRFs
Number of subjects: 6251
Study: 31784451

Group type: EXPERIMENTAL
Intervention: r-axSpA
Number of subjects: 669

Group type: COMPARATOR
Intervention: nr-axSpA
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 669
Study: 31784744

Group type: EXPERIMENTAL
Intervention: Normal menstruation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Irregular menstruation/menopause
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Perimenstrual/menopausal phenotype
Number of subjects: 82

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 82

Group type: COMPARATOR
Intervention: Gene microarray data (n = 53)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Fat cell size
Number of subjects: 82
Study: 31784934

Group type: EXPERIMENTAL
Intervention: Experimental group (patients with adenomatous polyps of the colon and yang-deficiency constitution)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (patients without colon polyps and with balanced constitution)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 119
Study: 31785185

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (Multidimensional Fatigue Inventory, patient global assessment of disease activity [PtGA], Short Form 36 health survey [SF-36], Brief Illness Perception Questionnaire)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Physician global assessment of disease activity (PhGA)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Laboratory outcomes (C-reactive protein [CRP] level, erythrocyte sedimentation rate [ESR])
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Imaging outcomes (PETVAS, a qualitative score of vascular involvement)
Number of subjects: 112
Study: 31785259

Group type: EXPERIMENTAL
Intervention: Total hyocholic acid (HCA)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Total HCA/total chenodeoxycholic acid (CDCA) ratio
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Fasting plasma BAs
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 6α-hydroxylated BAs
Number of subjects: 205
Study: 31785337

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT) to at-risk areas in the involved neck (60-66 Gy) and uninvolved neck (54 Gy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative RT avoiding the resected primary tumor site
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Feeding tube dependence rates during and after RT
Number of subjects: 60
Study: 31785503

Group type: EXPERIMENTAL
Intervention: Insulin treatment (monotherapy or combination therapy)
Number of subjects: 249
Study: 31785703

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Procedural sedation
Number of subjects: 0
Study: 31785831

Group type: EXPERIMENTAL
Intervention: Intrathecal autologous adipose tissue-derived mesenchymal stem cells (AD-MSCs) - 100 million cells infused after a standard lumbar puncture at the L3-4 level, administered 11 months after injury.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intrathecal autologous adipose tissue-derived mesenchymal stem cells (AD-MSCs)
Number of subjects: 1
Study: 31786043

Group type: EXPERIMENTAL
Intervention: On-hour admission
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Off-hour admission
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: On-hour admission without neurosurgical interventions
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: On-hour admission without hematoma evacuation surgery
Number of subjects: 1269
Study: 31786124

Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Radiotherapy (55.8 Gy)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (chemotherapy and 55.8 Gy radiotherapy)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (chemotherapy and 45 Gy radiotherapy, then surgery and radiotherapy boost)
Number of subjects: 529
Study: 31786235

Group type: EXPERIMENTAL
Intervention: CTV registration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bone registration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Diaphragm registration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Average peak-to-peak respiratory tumor motion
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Recommendation
Number of subjects: 56
Study: 31786276

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost technique (60 Gy high dose and 54 Gy low dose in 30 fractions)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 53
Study: 31786971

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure ≥180 mm Hg
Number of subjects: 300193

Group type: COMPARATOR
Intervention: Normal blood pressure levels
Number of subjects: 300193

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure grade 1
Number of subjects: 300193

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure grade 2
Number of subjects: 300193

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure grade 3
Number of subjects: 300193

Group type: EXPERIMENTAL
Intervention: Screening for ASCVD
Number of subjects: 300193

Group type: EXPERIMENTAL
Intervention: Treatment for ASCVD
Number of subjects: 300193
Study: 31787498

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) glibenclamide (BIIB093; glyburide) treatment
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Admission NIHSS
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: ACA territory infarct volume
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Infarct lesions involving the anterior cerebral artery (ACA) territory and its middle cerebral artery (MCA) border zone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Left MCA infarcts
Number of subjects: 83
Study: 31787527

Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST) assessments including cold pressor test, conditioned pain modulation paradigm, repetitive pin-prick stimuli, and pressure stimulation.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Quantitative sensory testing (QST) assessments in patients with CP.
Number of subjects: 182
Study: 31788323

Group type: EXPERIMENTAL
Intervention: Healthy Parent Carers (HPC) programme - peer-led, group-based intervention with online resources
Number of subjects: 0

Group type: COMPARATOR
Intervention: Access to online resources only (control)
Number of subjects: 0
Study: 31789119

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31789601

Group type: EXPERIMENTAL
Intervention: MMA+ (Mindfulness Meditation app)
Number of subjects: 189

Group type: COMPARATOR
Intervention: MMA- (Mindfulness Meditation without the app)
Number of subjects: 189
Study: 31789686

Group type: EXPERIMENTAL
Intervention: Physical activity and diet intake interventions
Number of subjects: 0
Study: 31789834

Group type: EXPERIMENTAL
Intervention: Normoxia (brain tissue oxygen tension > 20 mm Hg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hypoxia (brain tissue oxygen tension < 20 mm Hg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of normoxia vs hypoxia
Number of subjects: 14
Study: 31789897

Group type: EXPERIMENTAL
Intervention: Transnasal flexible endoscopic laryngoscopy (TFEL)
Number of subjects: 169
Study: 31789931

Group type: EXPERIMENTAL
Intervention: Allergen-specific immune signature-guided dietary elimination therapy
Number of subjects: 24
Study: 31790126

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 927
Study: 31790472

Group type: EXPERIMENTAL
Intervention: Bayesian network algorithm applied to SLE gene network using transcriptomic data
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Bayesian network algorithm
Number of subjects: 1760
Study: 31790766

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-based direct-acting antivirals (DAAs)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Sofosbuvir-free direct-acting antivirals (DAAs)
Number of subjects: 481
Study: 31790959

Group type: EXPERIMENTAL
Intervention: EndoPredict® (EpClin) test
Number of subjects: 200
Study: 31791337

Group type: EXPERIMENTAL
Intervention: Functional small airway disease (fSAD) defined by CT and Parametric Response Mapping methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT-defined emphysema
Number of subjects: 0
Study: 31791338

Group type: EXPERIMENTAL
Intervention: Neighbourhood Team Development (NTD) intervention, a 30-month standardized training and implementation plan.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NTD intervention
Number of subjects: 6
Study: 31792136

Group type: EXPERIMENTAL
Intervention: Interleukin-22 (IL22)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeting IL22
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological modulation of the ER stress response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibody blockade of IL12p40
Number of subjects: 0
Study: 31792576

Group type: EXPERIMENTAL
Intervention: Single-layer renorrhaphy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional two-layer renorrhaphy
Number of subjects: 0
Study: 31792696

Group type: EXPERIMENTAL
Intervention: Chronic migraine patients (CM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 52
Study: 31792872

Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 5341

Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 5341

Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 5341
Study: 31792889

Group type: EXPERIMENTAL
Intervention: Needle-free connectors (NFC)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Three-way hubs closed by caps (Control)
Number of subjects: 111
Study: 31793850

Group type: EXPERIMENTAL
Intervention: FDG PET/MRI with dedicated liver and rectal MRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest and abdominopelvic CT
Number of subjects: 0
Study: 31793891

Group type: EXPERIMENTAL
Intervention: PAGETEX medical device with Metvixia, administered in two PDT sessions at 15-day intervals (Metvixia incubation for 30 minutes and 635 nm red light illumination for 2 hours and 30 minutes, total fluence of 12 J/cm²)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PAGETEX medical device with Metvixia, administered in two PDT sessions at 15-day intervals
Number of subjects: 24
Study: 31793897

Group type: EXPERIMENTAL
Intervention: selfBACK app in addition to usual care
Number of subjects: 350

Group type: COMPARATOR
Intervention: usual care only
Number of subjects: 350
Study: 31794031

Group type: EXPERIMENTAL
Intervention: Support for HIV infection and substance use treatment
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of pol sequences
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS, env region)
Number of subjects: 445
Study: 31794605

Group type: EXPERIMENTAL
Intervention: Gender-affirming treatment in transgender men (TM)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Gender-affirming treatment in transgender women (TW)
Number of subjects: 23
Study: 31794700

Group type: EXPERIMENTAL
Intervention: Graded transthoracic contrast echocardiography (TTCE)
Number of subjects: 32
Study: 31794742

Group type: EXPERIMENTAL
Intervention: VCD (MANTA; Teleflex/Essential Medical, Malvern, PA)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Surgical cutdown
Number of subjects: 268
Study: 31795071

Group type: EXPERIMENTAL
Intervention: Convection-Enhanced Delivery of a TGFβ
Number of subjects: 0
Study: 31795926

Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-circumcised men)
Number of subjects: 0
Study: 31795981

Group type: EXPERIMENTAL
Intervention: Mass Testing, Treatment and Tracking (MTTT)
Number of subjects: 5000
Study: 31796469

Group type: EXPERIMENTAL
Intervention: MK-3475 (200 mg every 21 days) in combination with BCG
Number of subjects: 20

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 20
Study: 31796491

Group type: EXPERIMENTAL
Intervention: Regional cerebral oxygen saturation (rSO2) monitoring during surgery
Number of subjects: 95
Study: 31796939

Group type: EXPERIMENTAL
Intervention: Preoperative chemical vestibular ablation with 0.5 - 1.0 mL of 40 mg/mL nonbuffered gentamicin administered in three intratympanic instillations.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no preoperative gentamicin treatment).
Number of subjects: 32
Study: 31796953

Group type: EXPERIMENTAL
Intervention: High-fructose diet (150 g daily) for 8 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: NAFLD patients (positive control)
Number of subjects: 10
Study: 31797105

Group type: EXPERIMENTAL
Intervention: IgM-enriched immunoglobulins (Pentaglobin) 250 mg/kg (5 mL/kg) per day for 72 hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 19
Study: 31798447

Group type: EXPERIMENTAL
Intervention: Ayahuasca (one dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31798516

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31798754

Group type: EXPERIMENTAL
Intervention: Protein-enriched milk (2 × 20 g protein/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbohydrates
Number of subjects: 0
Study: 31798950

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 31798984

Group type: EXPERIMENTAL
Intervention: Samvedana Plus
Number of subjects: 620

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 620
Study: 31799207

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of sorafenib and hepatic arterial infusion chemotherapy
Number of subjects: 0
Study: 31799472

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31799498

Group type: EXPERIMENTAL
Intervention: TNF inhibitors (infliximab, etanercept, adalimumab, MTX)
Number of subjects: 4315

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 4315

Group type: COMPARATOR
Intervention: Non-biologic/methotrexate (MTX)
Number of subjects: 4315

Group type: EXPERIMENTAL
Intervention: Non-biologic/non-MTX
Number of subjects: 4315
Study: 31800543

Group type: EXPERIMENTAL
Intervention: Fecobionics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Balloon Expulsion Test (BET)
Number of subjects: 20
Study: 31801624

Group type: EXPERIMENTAL
Intervention: Utomilumab 1.2-5 mg/kg or 100 mg flat dose every 4 weeks plus mogamulizumab 1 mg/kg (weekly in Cycle 1 followed by biweekly in Cycles ≥2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Utomilumab/mogamulizumab combination
Number of subjects: 24
Study: 31801732

Group type: EXPERIMENTAL
Intervention: Tremelimumab monotherapy (750 mg via intravenous infusion every 4 weeks for seven cycles, then every 12 weeks for two additional cycles)
Number of subjects: 32
Study: 31802302

Group type: EXPERIMENTAL
Intervention: < 10 Ncm insertion torque
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ~ 30 Ncm insertion torque
Number of subjects: 12
Study: 31802369

Group type: EXPERIMENTAL
Intervention: Vagal modulation of arousal (indexed by respiratory sinus arrhythmia - RSA)
Number of subjects: 105
Study: 31802410

Group type: EXPERIMENTAL
Intervention: FOLFIRI + Sunitinib (S)
Number of subjects: 23
Study: 31802485

Group type: EXPERIMENTAL
Intervention: Gastric suctioning
Number of subjects: 61

Group type: COMPARATOR
Intervention: Erythromycin infusion
Number of subjects: 61
Study: 31802967

Group type: EXPERIMENTAL
Intervention: Ensemble method combining k-nearest neighbor and supervised fuzzy c-means
Number of subjects: 3962

Group type: EXPERIMENTAL
Intervention: k-nearest neighbor
Number of subjects: 3962

Group type: EXPERIMENTAL
Intervention: Supervised fuzzy c-means
Number of subjects: 3962
Study: 31803056

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Enriched in High Quality Extra Virgin Olive Oil
Number of subjects: 0
Study: 31803089

Group type: EXPERIMENTAL
Intervention: Bergen 4-day treatment (B4DT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Self-help (SH)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 48
Study: 31803481

Group type: EXPERIMENTAL
Intervention: DSPN+
Number of subjects: 304

Group type: COMPARATOR
Intervention: DSPN-
Number of subjects: 304

Group type: COMPARATOR
Intervention: NGT
Number of subjects: 304
Study: 31803494

Group type: COMPARATOR
Intervention: Allocation to 60 min school PA/week
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Each 10 cm shorter body height
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Each unit higher body mass index (BMI)
Number of subjects: 199
Study: 31803487

Group type: EXPERIMENTAL
Intervention: Prehospital 12-lead ECG (PHECG)
Number of subjects: 0
Study: 31803509

Group type: EXPERIMENTAL
Intervention: Appointment scheduling intervention
Number of subjects: 8385

Group type: COMPARATOR
Intervention: Control group (first come, first served)
Number of subjects: 8385
Study: 31803694

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31803710

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31803847

Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection (CHMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection (CHMI)
Number of subjects: 0
Study: 31804102

Group type: EXPERIMENTAL
Intervention: IRT-calibrated CAPS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-calibrated CAPS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncalibrated MPSS scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncalibrated CAPS scores
Number of subjects: 0
Study: 31804281

Group type: EXPERIMENTAL
Intervention: Web-based legacy intervention
Number of subjects: 81